Skip to main content

Published locations for Ustekinumab leads to high 6-week clinical response and 44-week remission rates

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ustekinumab leads to high 6-week clinical response and 44-week remission rates

User login

  • Reset your password
  • /content/ustekinumab-leads-high-6-week-clinical-response-and-44-week-remission-rates
  • /familypracticenews/article/118125/gastroenterology/ustekinumab-leads-high-6-week-clinical-response
  • /gihepnews/article/118125/gastroenterology/ustekinumab-leads-high-6-week-clinical-response-and-44
  • /internalmedicinenews/article/118125/gastroenterology/ustekinumab-leads-high-6-week-clinical-response
  • /internalmedicine/article/118125/gastroenterology/ustekinumab-leads-high-6-week-clinical-response-and
  • /familymedicine/article/118125/gastroenterology/ustekinumab-leads-high-6-week-clinical-response-and